At the pulse of heart disease
We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.
Mode of Action
The video illustrates how CDR132L operates in cardiac cells to reverse adverse cardiac remodeling and restore normal cellular functions.
CDR132L is currently being evaluated in HF-REVERT Phase 2 Clinical Study in heart failure patients after myocardial infarction.
News
DIA/FDA Oligonucleotide-Based Therapeutics Conference
Event ·
October 28–30, 2024
· Washington DC, USA
International Society for Heart Research SEA 2024 Meeting
Event ·
October 1–4, 2024
· Singapore
Dr. Claudia Ulbrich interviewed by Philip Hemme in the flot.bio Podcast
Insight into the history of Cardior, its lead compound CDR132L and the €1B acquisition by Novo Nordisk in an hour-long conversation with Philip Hemme in flot.bio - Europe’s Biotech Podcast.
Cardior News ·
May 9, 2024
